Big Medicine threatens your wallet and your health. But there is a solution.

A wave of legal victories and policy scrutiny is targeting pharmacy benefit managers (PBMs) and health insurers, with Arkansas’ court ruling in favor of CVS marking a key moment. Coverage highlights escalating tensions: *The New York Times* reports lawmakers are pushing bills to curb insurer dominance, while *JD Supra* notes state regulations face legal hurdles. *The Daily Economy* argues administrative fixes alone won’t lower drug prices, framing the debate over structural reforms.

Outlets emphasize the dual pressure on PBMs—both from state-level laws (like Arkansas’) and federal legislative efforts. *BenefitsPRO* and *MS NOW* frame the issue as a consumer crisis, linking PBM practices to rising costs and access barriers. Legal analyses in *JD Supra* underscore the patchwork of challenges, with appeals courts shaping outcomes.

The narrative splits between calls for systemic change and incremental policy tweaks. Watch for: - Whether Arkansas’ ruling sets a precedent for other states challenging PBM networks. - Legislative progress on bills targeting insurer power, particularly in Congress. - Industry responses, including potential counter-lobbying or legal maneuvers by PBMs and insurers. - Broader public debate on whether proposed solutions (e.g., transparency laws, direct negotiations) will address root causes of high drug prices.